Ohio board rejects medical marijuana for autism
Cleveland.com highlights UC expert's testimony to State Medical Board
The State Medical Board of Ohio rejected proposals to add autism and female orgasmic difficulty disorder to the list of qualified conditions for which patients can obtain medical marijuana.
The decision came following testimony from experts including the University of Cincinnati's Craig Erickson, MD, associate professor in UC's College of Medicine and a Cincinnati Children's Hospital physician researcher, who spoke against the inclusion of autism on the approved conditions list.
Cleveland.com highlighted Erickson's and other experts' testimony in an article about the board's decision. Erickson told the board adults and children with autism are increasingly testing positive for THC even though there are not reports of clearly positive change in autism spectrum disorder patients.
Erickson added he's concerned that some patients are not capable of giving consent for cannabis, due to the communication deficits that are part of their autism spectrum disorder.
Read the Cleveland.com article.
Featured photo at top of marijuana leaves. Photo/Jeff W/Unsplash.
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.